abstract |
Materials and methods for identifying and treating cancer patients who are likely to respond to chemo-immunotherapy (CIT) and other cancer treatments are provided herein, including materials and methods for using CX3CR1 to identify PD-1 therapy-responsive CD8+ T cells that withstand the toxicity of chemotherapy during combined CIT. |